Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLBE | ISIN: SE0012675361 | Ticker-Symbol: 6IRA
Frankfurt
28.03.24
08:03 Uhr
1,380 Euro
-0,050
-3,50 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IRLAB THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
IRLAB THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur IRLAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoIRLAB Therapeutics - FDA thumbs up to mesdopetam's Phase III plan119IRLAB Therapeutics has confirmed the FDA's alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following receipt of the minutes from its end-of-Phase...
► Artikel lesen
22.03.IRLAB Therapeutics: IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam901GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments...
► Artikel lesen
20.03.IRLAB Therapeutics - Mesdopetam's potential highlighted in PD-psychosis172The recent scientific paper in Neurotherapeutics discusses the encouraging preclinical studies focused on the characterisation of the neurophysiological brain state in Parkinson's disease psychosis...
► Artikel lesen
19.03.IRLAB Therapeutics: IRLAB's Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis242GOTHENBURG, SE / ACCESSWIRE / March 19, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 19 March 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
29.02.IRLAB Therapeutics: IRLAB to Present at Life Science-dagen in Gothenburg and have a Fireside Chat with ABG214GOTHENBURG, SWEDEN / ACCESSWIRE / February 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 29, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
28.02.IRLAB Therapeutics: IRLAB to Present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7372GOTHENBURG, SWEDEN / ACCESSWIRE / February 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 28, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering...
► Artikel lesen
27.02.IRLAB Therapeutics: IRLAB to Present Clinical and Preclinical Data at the AD/PD 2024: 18th International Conference on Alzheimer's & Parkinson's Diseases197GOTHENBURG, SWEDEN / ACCESSWIRE / February 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
23.02.IRLAB Therapeutics - Positive FDA mesdopetam outlook following EoP2222IRLAB Therapeutics reported positive feedback from its FDA end-of-Phase II (EoP2) meeting earlier in the week for mesdopetam. According to management, the meeting was held in a constructive and engaging...
► Artikel lesen
22.02.IRLAB Therapeutics: IRLAB has Completed a Successful End-of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam428GOTHENBURG, SWEDEN / ACCESSWIRE / February 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 22 February 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
12.02.IRLAB Therapeutics - Timeline refresh with numerous inflection points241IRLAB has reported FY23 results and provided operational and regulatory updates, including an end-of-Phase II (EoP2) meeting with the FDA for mesdopetam and extended patent protection for pirepemat...
► Artikel lesen
07.02.IRLAB Therapeutics: IRLAB Publishes Year-end Report for the Period January-December 2023479GOTHENBURG, SWEDEN / ACCESSWIRE / February 7, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the...
► Artikel lesen
06.02.IRLAB Therapeutics: IRLAB's Pioneering Phase IIb Study with Pirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines259GOTHENBURG, SWEDEN / ACCESSWIRE / February 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 6, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) is a company...
► Artikel lesen
03.01.IRLAB Therapeutics - End-of-Phase II FDA meeting set391IRLAB Therapeutics has scheduled an end-of-Phase II (EoP2) meeting (on 20 February 2024) with the US FDA for the mesdopetam programme. This marks an important milestone for IRLAB as it will evaluate...
► Artikel lesen
03.01.IRLAB Therapeutics: IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program762GOTHENBURG, SWEDEN / ACCESSWIRE / January 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, January 3, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
02.01.IRLAB Therapeutics - SEK55m loan enhances headroom past key catalysts243IRLAB Therapeutics has announced a new loan facility of up to SEK55m with Formue Nord to support its development programmes. Provided the facility is fully drawn down, we estimate it will extend IRLAB's...
► Artikel lesen
27.12.23IRLAB Therapeutics: IRLAB Extends CEO Appointment282GOTHENBURG, SWEDEN / ACCESSWIRE / December 27, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 27, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
22.12.23IRLAB Therapeutics - IRL757 Phase I-ready with support from MJFF330IRLAB Therapeutics has announced that IRL757, a drug candidate being developed for the treatment of apathy in Parkinson's disease (PD) and other neurological conditions, is now Phase I-ready. Management...
► Artikel lesen
21.12.23IRLAB Therapeutics: IRLAB Receives Grant from The Michael J. Fox Foundation to Support Development of IRL757 for the Treatment of Apathy293GOTHENBURG, SWEDEN / ACCESSWIRE / December 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, December 21, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
21.12.23IRLAB Therapeutics: IRLAB's Drug Candidate IRL757 is Phase I Ready198GOTHENBURG, SWEDEN / ACCESSWIRE / December 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 21, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
19.12.23IRLAB Therapeutics - Mesdopetam's clinical roadmap laid out277IRLAB has submitted a request for an end-of-Phase II meeting (EoP2) with the FDA for its lead asset, mesdopetam, to chart the Phase III roadmap for the drug. According to FDA guidelines, the agency...
► Artikel lesen
Seite:  Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1